Q1 2025 saw lower sales and a negative operating result, but strong cash flow from new convertible loan financing. Strategic investments in technology and product development position Gasporox for future growth in expanding quality control markets.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.